Most Read Articles
19 Jun 2019
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
2 days ago
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, 3 days ago
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, 3 days ago
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.

Memantine shows therapeutic potential in ADHD

02 Feb 2019

Use of memantine in the treatment of adults with attention deficit hyperactivity disorder (ADHD) appears to reduce symptoms associated with the condition, in addition to having a tolerable safety profile, a study has shown.

The study randomized 40 patients aged 18–45 years with ADHD to receive memantine (n=20; mean age 34.7 years) or placebo (mean age 31.5 years) for 6 weeks. Treatment was administered at 10 mg/day in the first week and then 20 mg/day thereafter. All patients completed the Conners' screening questionnaire.

Results showed significant differences in behaviour and attention deficit between the two groups after 6 weeks of treatment (p<0.001). Compared with placebo, memantine produced improvements from baseline in the following symptoms: inattention/memory problems, hyperactivity/restlessness and impulsivity/emotional lability.

Moreover, the ADHD Index significantly decreased over the treatment course in the memantine group (from 56.4 at baseline to 43.9 at week 3 and 36.7 at week 6) but remained stable in the placebo group (from 59.3 at baseline to 57.2 at week 3 and 59.7 at week 6).

In terms of safety, memantine was tolerable, and side effects were mild in severity. Commonly reported adverse events included dizziness, confusion, constipation, back pain and sleepiness.

The findings suggest that memantine is safe and effective for treating ADHD, researchers said. However, further studies are needed to evaluate such effects.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Psychiatry - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
19 Jun 2019
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
2 days ago
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, 3 days ago
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, 3 days ago
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.